Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Expression Pathology Raises $6.5 Million to Develop Personalized Medicine Assays for Protein Biomarkers in FFPE Tissue

Abstract:
Proprietary tissue proteomics platform and strategic vision for future growth in pre-clinical and clinical biomarker research spur new financing

Expression Pathology Raises $6.5 Million to Develop Personalized Medicine Assays for Protein Biomarkers in FFPE Tissue

Rockville, MD | Posted on April 20th, 2009

Expression Pathology Inc., a leading developer of technology for tissue protein analysis, announced that it has received additional financing of $6.5 million. The financing was led exclusively by Abraxis BioScience, a fully integrated, global biotechnology company.

The financing will be used to apply Expression Pathology's patented Liquid Tissue(R) proteomics technology in developing proprietary, personalized medicine clinical assays that relate measurement of protein biomarkers of drug response and disease prognosis to specific patient treatment decisions.

"Formalin-fixed paraffin-embedded tissue is the standard form of patient tumor and biopsy samples worldwide," said Casey Eitner, President and CEO of Expression Pathology. "We believe the ability of our technology to interrogate archived tissue collections to discover and validate protein biomarkers that relate to disease progression, drug response and toxicity, and to measure those biomarkers accurately in standard tissue from clinical trials and medical care, will translate into a tremendously valuable asset. We are pleased that Abraxis shares this vision."

"Expression Pathology has created unique technology solutions for tissue protein analysis," said Lex Van der Ploeg, Senior Vice President of Integrative Medicine and Translational Science at Abraxis, and a Board Member of Expression Pathology. "Abraxis is looking forward to harnessing these technologies and clinical assays in its development and diagnostic programs, and to benefiting from the value which is being created by growing interest from biopharmaceutical companies and academic research groups, who are increasingly seeking to access Expression Pathology's technologies to accelerate their own research and drug development."

About Abraxis BioScience

Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE), which is based on the company's proprietary tumor targeting technology known as the nab(R) platform. The first FDA approved product to use this nab(R) platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information, please visit www.abraxisbio.com.

####

About Expression Pathology Inc.
Expression Pathology Inc., Gaithersburg, MD, has developed proprietary techniques for discovery and analysis of protein biomarkers in tissue. The company's Director(R) laser microdissection slides enable precise, rapid, automated collection of specific cellular features from tumor tissue. Its Liquid Tissue(R) reagent technology makes possible discovery and measurement of proteins in formalin-fixed tissue by mass spectrometry. EPI employs its Liquid Tissue(R) proteomics platform in its own and collaborative biomarker discovery and assay development programs, and offers contract research services and products.

For more information, please click here

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014

Gold nanoparticle chains confine light to the nanoscale October 31st, 2014

'Nanomotor lithography' answers call for affordable, simpler device manufacturing October 31st, 2014

Device invented at Johns Hopkins provides up-close look at cancer on the move: Microscopic view of metastasis could give insight about how to keep cancer in check October 31st, 2014

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

7th Nanotechnology Festival, Exhibition Kicks Off Work in Iran October 7th, 2014

Harris & Harris Group Letter to Shareholders on Website August 19th, 2014

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 August 12th, 2014

Nanomedicine

Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014

Production of Biocompatible Polymers in Iran October 30th, 2014

Amorphous Coordination Polymer Particles as alternative to classical nanoplatforms for nanomedicine October 30th, 2014

'Electronic skin' could improve early breast cancer detection October 29th, 2014

Announcements

Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014

Gold nanoparticle chains confine light to the nanoscale October 31st, 2014

'Nanomotor lithography' answers call for affordable, simpler device manufacturing October 31st, 2014

Device invented at Johns Hopkins provides up-close look at cancer on the move: Microscopic view of metastasis could give insight about how to keep cancer in check October 31st, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE